NexaBiome
Sean Nicolson is an experienced investment professional with a strong background in venture capital and company governance. Currently serving as EIS Funds Partner at Northstar Ventures UK since May 2023, Sean is responsible for the development and launch of EIS, SEIS, and retail investor-focused investment funds. Notable roles include Investor and Non-Executive Director positions at Advanced Electric Machines, amBX Ltd, and Nexabiome, as well as an Investor and Board Observer at Magnitude Biosciences. Sean has also contributed as Director and Trustee of Tyneside Cinema since January 2023, focused on enriching community engagement through film. Previous experience includes non-executive roles at Asimilar Group plc and executive leadership at e-Therapeutics PLC. Sean holds a BA (Hons) in Law from the University of Durham, St John's College, completed in 1989.
This person is not in any teams
NexaBiome
NexaBiome's patented technology enables bacteriophages to be covalently attached to a wide variety of substrates; this gives them enhanced stability for use in a variety of applications which address two of the world's major challenges, antibiotic resistance and food supply and sustainability. By attaching specific bacteriophages to fish and animal feeds, we can reduce, augment or even substitute for antibiotics in the food chain. This lets us target both human and animal pathogens, such as E. coli, Listeria, Campylobacter, Salmonella, Streptococcus, Pseudomonas, Flavobacteria and others. As our bonded phage products can be stable for months or even years and are less sensitive to temperature and other environmental factors, they can be effectively shipped and applied in versatile formulations Bacteriophages also have many potential human applications when antibiotics fail. Phages are expert microbiome engineers and can specifically alter the bacterial microbiome of the human gut, skin, vagina, lung and other micro-environments. Microbiome engineering has important applications to irritable bowel syndrome, acne, bacterial vaginosis and bacterial lung diseases. Our ability to attach bacteriophages to micro- and nano-particles and to enhance their stability and active life span, can potentially enhance their effectiveness in these applications, whether as part of a probiotic supplement or as encapsulated powders/beads.